Mallinckrodt

DUBLIN, Nov. 16, 2020 /PRNewswire/ — Mallinckrodt plc, a global biopharmaceutical company, today announced findings from a large U.S. database review

DUBLIN, Nov. 16, 2020 /PRNewswire/ — Mallinckrodt plc, a global biopharmaceutical company, today announced results from a post hoc analysis of

DUBLIN – November 13, 2020 – Mallinckrodt plc, a global biopharmaceutical company, today announced that the Company recently participated in an

DUBLIN, Nov. 10, 2020 /PRNewswire/ — Mallinckrodt plc, a global biopharmaceutical company, today announced initiation of a retrospective chart review study,

DUBLIN, Oct. 29, 2020 /PRNewswire/ — Mallinckrodt plc, a global biopharmaceutical company, today announced results from two post-hoc studies of its

DUBLIN, Ireland, October 14, 2020 – Mallinckrodt plc (“Mallinckrodt” or the “Company”) today announced that it has received approvals from

DUBLIN, Oct. 12, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK) (“Mallinckrodt” or the “Company”) today announced that it has voluntarily initiated

DUBLIN, Sept. 14, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug

— €50,000 award goes to University Hospital of Lille in France to fund researchinto the potential impact of Extracorporeal Photopheresis

ST. LOUIS, Aug. 24, 2020 /PRNewswire/ — Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, today announced that its Specialty Generics business

STAINES-UPON-THAMES, United Kingdom, Aug. 10, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food

DUBLIN, Aug. 4, 2020 /PRNewswire/ — Second quarter net sales of $166.5 million net of the retrospective one-time Acthar® Gel

DUBLIN, July 15, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal

– In a rare dual-review process, two independent advisory committees to the Australian Minister for Health recommend reimbursement based on

STAINES-UPON-THAMES, United Kingdom, July 9, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will

STAINES-UPON-THAMES, United Kingdom, July 7, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and

STAINES-UPON-THAMES, United Kingdom, June 17, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 23,

STAINES-UPON-THAMES, United Kingdom, June 15, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced its disappointment with the

STAINES-UPON-THAMES, United Kingdom, June 15, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present data

STAINES-UPON-THAMES, United Kingdom, June 11, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from

STAINES-UPON-THAMES, United Kingdom, June 9, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has

STAINES-UPON-THAMES, United Kingdom, June 1, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it

STAINES-UPON-THAMES, United Kingdom, May 5, 2020 /PRNewswire/ — First quarter net sales of $665.8 million, with diluted loss per share

STAINES-UPON-THAMES, United Kingdom, May 4, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that its observational registry

STAINES-UPON-THAMES, United Kingdom, April 30, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it is supporting